ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.

Biotechnology

Health Care

Life Sciences

Medical Devices

Therapeutics

ProKidney Corp.

ProKidney Corp.'s headquarters in Winston-Salem, NC, United States

Bruce Culleton

Emily Butler

Carla Poulson

Kathleen Conde

James Coulston

Todd Girolamo

Description

People (12)

Kipp Hollingsworth

Heather Verba

Juliane Bush

Caroline Diaz

Hayley Squires

Neil Robbins

James Coulston

Jill Kuharsky

Rachel Scott

Kristina Lester

Jerome Tillery

Dominic Justewicz

Jobs